Can Operational Execution Support DaVita's Q4 Performance?

Key Takeaways DaVita's Q4 2025 is expected to benefit from improved treatment mix and aged claims resolution.DVA may see stronger earnings driven by higher revenue per treatment and disciplined cost control.DaVita's tech investments and IKC timing could help offset pressure from missed treatments and mortality.DaVita Inc. (DVA) is scheduled to report fourth-quarter 2025 results on Feb. 2, 2026, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of $2.51 lagged the Za ...